ArticleMedical & biological engineering & computing2025
Deep learning-based prognostic assessment of polyploid giant cancer cells and mitotic figures in liver cancer.
Article in Medical & biological engineering & computing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Primary liver cancer is among the most lethal malignancies, with cell-level structural features such as polyploid giant cancer cells and mitotic figures strongly associated with poor patient prognosis. However, the quantification of these features is hindered by a shortage of pathologists, high workloads, and subjective discrepancies. To address these challenges, we leverage deep learning algorithms to enable the rapid detection of cell-level features, combining this capability with survival analysis to establish a novel, practical prognostic risk assessment system for liver cancer diagnosis and treatment. In collaboration with Peking University Shenzhen Hospital, we collected 172 liver cancer cases, comprising 340 pathology images, to construct the HCCP&M dataset. Our full-process calculation system integrates cell-level feature detection and survival analysis. During the detection phase, the CellFDet framework achieves F1 scores of 0.814, 0.819, and 0.935 for detecting polyploid giant cancer cells, mitotic figures, and general cells, respectively. In the survival analysis phase, patients were stratified into high-risk and low-risk groups based on the polyploid giant cancer cell index (P < 0.0001) and the mitotic index (P = 0.0025), with both indices demonstrating significant survival differences. Correlation analysis further confirmed these features as independent prognostic indicators for liver cancer. Our proposed system not only enables accurate detection of cell-level structural features but also provides reliable survival predictions, offering a valuable tool for improving the prognosis and treatment planning for liver cancer patients.
Indexed as
Identifiers
40332632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.